Adenylyl cyclase type 5 (AC5) is an essential mediator of morphine action

Proceedings of the National Academy of Sciences of the United States of America
Kyoung-Shim KimPyung-Lim Han

Abstract

Opioid drugs produce their pharmacological effects by activating inhibitory guanine nucleotide-binding regulatory protein-linked mu, delta, and kappa opioid receptors. One major effector for these receptors is adenylyl cyclase, which is inhibited upon receptor activation. However, little is known about which of the ten known forms of adenylyl cyclase are involved in mediating opioid actions. Here we show that all of the major behavioral effects of morphine, including locomotor activation, analgesia, tolerance, reward, and physical dependence and withdrawal symptoms, are attenuated in mice lacking adenylyl cyclase type 5 (AC5), a form of adenylyl cyclase that is highly enriched in striatum. Furthermore, the behavioral effects of selective mu or delta opioid receptor agonists are lost in AC5-/- mice, whereas the behavioral effects of selective kappa opioid receptor agonists are unaffected. These behavioral data are consistent with the observation that the ability of a mu or delta opioid receptor agonist to suppress adenylyl cyclase activity was absent in striatum of AC5-/- mice. Together, these results establish AC5 as an important component of mu and delta opioid receptor signal transduction mechanisms in vivo and provide furthe...Continue Reading

References

Jun 5, 1986·European Journal of Pharmacology·C T O'Shaughnessy, P M Headley
Aug 1, 1995·Proceedings of the National Academy of Sciences of the United States of America·L J SimS R Childers
Feb 14, 1995·European Journal of Pharmacology·F Rodríguez De FonsecaM Navarro
Dec 15, 1994·The Journal of Comparative Neurology·A MansourS J Watson
Jan 1, 1996·Annual Review of Pharmacology and Toxicology·R K SunaharaA G Gilman
Jan 1, 1996·Journal of Addictive Diseases·M J Kreek
Jan 1, 1997·Journal of Clinical Neurophysiology : Official Publication of the American Electroencephalographic Society·W D Willis, K N Westlund
Feb 18, 1997·Proceedings of the National Academy of Sciences of the United States of America·I SoraG R Uhl
Jul 1, 1997·Pharmacology, Biochemistry, and Behavior·T S Shippenberg, W Rea
Oct 6, 1997·Science·E J Nestler, G K Aghajanian
Feb 28, 1998·Current Biology : CB·S R Childers
Aug 26, 1998·Drug and Alcohol Dependence·R A Wise
Sep 30, 1998·The European Journal of Neuroscience·S Schulz, V Höllt
Oct 13, 1998·Neuron·G F KoobF E Bloom
Dec 22, 1999·Life Sciences·N Altier, J Stewart
Jun 3, 2000·Annual Review of Pharmacology and Toxicology·P Y LawH H Loh
Nov 14, 2000·Neuroscience·D L Tolbert, B R Clark
Dec 26, 2001·Brain Research. Brain Research Reviews·J G Liu, K J Anand
May 17, 2002·Progress in Neurobiology·Brigitte L Kieffer, Claire Gavériaux-Ruff
Aug 8, 2002·Proceedings of the National Academy of Sciences of the United States of America·Michel BarrotEric J Nestler
Dec 14, 2002·The Clinical Journal of Pain·Charles E Inturrisi
Jan 25, 2003·The European Journal of Neuroscience·Fernando BerrenderoOlga Valverde
Nov 19, 2003·The European Journal of Neuroscience·Vladimir I CheferToni S Shippenberg
Apr 6, 2004·Trends in Pharmacological Sciences·Eric J Nestler
Jun 15, 2004·Current Opinion in Neurobiology·Candice ContetKatia Befort

❮ Previous
Next ❯

Citations

Nov 14, 2007·Naunyn-Schmiedeberg's Archives of Pharmacology·Shinya KasaiKazutaka Ikeda
Oct 7, 2009·Psychopharmacology·Michael J McCarthyMaria Hadjiconstantinou
Apr 2, 2009·Nature Reviews. Drug Discovery·Sandra PierreKlaus Scholich
Dec 25, 2012·The Journal of Biological Chemistry·Riad EfendievCarmen W Dessauer
Aug 18, 2006·Molecular Pharmacology·Shuang LiCharles Chavkin
Feb 5, 2008·The Journal of Clinical Investigation·Christian ZöllnerMichael Schäfer
May 21, 2013·Antioxidants & Redox Signaling·Hai-Yu YangJin-Song Bian
Dec 15, 2010·Cellular and Molecular Life Sciences : CMLS·María Rodríguez-MuñozJavier Garzón
Apr 3, 2016·Mutation Research. Reviews in Mutation Research·Robert P Erickson
May 23, 2012·Trends in Pharmacological Sciences·Edward C EmeryPeter A McNaughton
Dec 18, 2010·Neuroscience Letters·Franklin A LeeLaura M Harrison
Dec 7, 2007·Anesthesiology Clinics·Gary McCleane, Howard S Smith
Oct 24, 2007·Peptides·Richard J Bodnar
Feb 27, 2007·The Medical Clinics of North America·Gary McCleane, Howard S Smith
May 1, 2009·Journal of Neuroscience Research·Kyoung-Shim Kim, Pyung-Lim Han
Aug 5, 2008·Journal of Neurochemistry·Kyoung-Shim KimPyung-Lim Han
Jan 3, 2013·Alcoholism, Clinical and Experimental Research·Daniela O ProcopioBoris Tabakoff
Apr 30, 2015·American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics·Arvis SulovariDawei Li
Jun 28, 2016·Pharmacological Reviews·Louis GendronGraciela Pineyro
Nov 24, 2016·Molecular Neurobiology·Hannah KimPyung-Lim Han
Sep 20, 2007·Journal of Neurochemistry·Thomas KroslakMary Jeanne Kreek
Sep 23, 2008·The Journal of Biological Chemistry·Ovidiu CosteKlaus Scholich
Aug 19, 2017·EMBO Molecular Medicine·Lei ZhangPing-Yee Law

❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.